2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 8: May 15, 2024 - Are Robots Taking Over? Augmented Intelligence in Dermatology & Practice Survival Strategies
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, May 15, 2024
8 PM ET / 5 PM PT
Are Robots Taking Over? Augmented Intelligence in Dermatology
Practice Survival Strategies
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
May 16, 2024
May 16, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify the application of AI for diagnosis
Review generative AI in dermatology
Outline the current reimbursement landscape
Review ways to use the entire physician fee schedule
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Mark Kaufmann, MD
Chief Medical Officer, Advanced Dermatology and Cosmetic Surgery
Clinical Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Consultant: Apogee Therapeutics, Avita Medical, Biofrontera, Dermagnostix, Dermtech,Incyte, Novan, Novartis, Rise Healthcare, Rivera Consulting, UCB, Verrica
Ownership Interest (privately held): Modernizing Medicine, Molesafe
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.